Glukóza Viaflo Baxter Czech

Glukóza Viaflo Baxter Czech is an intravenous solution containing glucose monohydrate as the sole active ingredient. It is supplied in a sterile liquid form intended for parenteral administration. The product is manufactured in the European Union and marketed without a specified strength on the label. Glukóza Viaflo Baxter Czech is used as a source of carbohydrate and energy in clinical settings where rapid glucose delivery is required.

Glukóza Viaflo Baxter Czech is employed in medical practice primarily to provide an immediate source of glucose for patients who cannot obtain adequate carbohydrate intake orally.

- Treatment of hypoglycemia when rapid correction of blood glucose is needed. - Maintenance of blood glucose levels during surgery or anesthesia. - Provision of calories in parenteral nutrition regimens. - Support for patients with prolonged fasting or severe malnutrition. - Dilution and carrier solution for certain intravenous medications.

Adverse reactions to intravenous glucose solutions are generally uncommon, but they can vary in frequency and severity.

Common: - Temporary increase in blood glucose concentration that resolves with monitoring. - Mild irritation or erythema at the catheter insertion site. - Slight nausea, vomiting, or abdominal cramping shortly after infusion. - Fluid overload signs such as peripheral edema when large volumes are administered.

Serious: - Marked hyperglycemia with osmotic diuresis, potentially precipitating ketoacidosis in susceptible individuals. - Immediate hypersensitivity reaction presenting as urticaria, bronchospasm, or hypotension. - Significant electrolyte disturbances, especially hyponatremia or hypokalemia, due to rapid shifts in plasma osmolality.

When using Glukóza Viaflo Baxter Czech, clinicians should observe several precautionary measures to minimize risks and ensure appropriate therapy.

- Verify patient’s blood glucose level before and during infusion to avoid overcorrection. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use caution in individuals with known hypersensitivity to glucose solutions or preservatives. - Monitor electrolytes, particularly sodium and potassium, during prolonged or high‑volume administration. - Avoid rapid infusion in neonates and infants due to risk of hyperosmolar injury. - Ensure aseptic technique to reduce the chance of catheter‑related infection. - Document the total amount of glucose administered for accurate nutritional accounting.

Glucose solutions can interact with other intravenous agents or patient conditions, influencing efficacy and safety.

Avoid: - Co‑administration with high‑dose insulin without appropriate glucose monitoring. - Simultaneous infusion of calcium‑containing solutions that may precipitate when mixed with dextrose. - Use with certain radiographic contrast media that can cause hyperglycemia.

Use with caution: - Concurrent administration of diuretics, which may exacerbate electrolyte shifts. - Patients receiving beta‑blockers, as they may mask signs of hypoglycemia. - Combination with vasopressors, requiring careful fluid balance assessment. - Overlapping infusion with parenteral nutrition formulas, to prevent excessive caloric load.